Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and

You are here:  Home >>  News >>  Market News >>  BMS acquires Celgene for an equity value of $74bn

BMS acquires Celgene for an equity value of $74bn

January 04, 2019 By pharmaceutical-technology

Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a cash and stock transaction with an equity value of $74bn; Celgene shares have been valued at $102.43 per share.

BMS acquires Celgene for an equity value of $74bn

The boards of directors of both companies have approved the deal.

According to the agreement, Celgene shareholders will receive one BMS share, the closing price of BMS stock was $52.43 on 2 January this year, and $50 in cash per share.

BMS expects a global, speciality biopharma company to be created with a particular focus on cancer, inflammation and immunologic diseases and cardiovascular diseases.

The new company will have a product portfolio comprising of nine products with more than $1bn in annual sales, six near-term launch opportunities with more than $15bn revenue potential and 50 high potential assets in the early stage pipeline offering positive growth.

BMS shareholders are expected to own 69% of the combined company, while Celgene shareholders will own the remaining 31%.

BMS CEO and chairman Giovanni Caforio said: “Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases.”

“As a combined entity, we will enhance our leadership positions across our portfolio, including in cancer and immunology and inflammation. We will also benefit from an expanded early- and late-stage pipeline that includes six expected near-term product launches.

“Together, our pipeline holds significant promise for patients, allowing us to accelerate new options through a broader range of cutting-edge technologies and discovery platforms.”

Celgene chairman and CEO Mark Alles said: “Combining with Bristol-Myers Squibb, we are delivering immediate and substantial value to Celgene shareholders and providing them meaningful participation in the long-term growth opportunities created by the combined company.

BMS expects the rate of return from this acquisition to be in excess of both its and Celgene’s cost capital and a more than 40% accretive of BMS’ earnings per share on a standalone basis in the first full year.

Register as Visitor to CPhI China 2019!

Editor's Note:

To apply for becoming a contributor of,

welcome to send your CV and sample works to us,



Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
live chat